References
- Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF. Carbapenemase-producing organisms: A global scourge. Clin Infect Dis. 2018;66(8):1290–7.
- Bianco G, Boattini M, Iannaccone M, Bondi A, Ghibaudo D, Zanotto E, Peradotto M, Cavallo R, Costa C. Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing Enterobacterales: A 2-year experience. J Glob Antimicrob Resist. 2021;24:411–4. doi:https://doi.org/10.1016/j.jgar.2021.02.008. 33621692
- Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497-17.
- Bhowmick T, Weinstein MP. Microbiology of meropenem-vaborbactam: A novel carbapenem beta-lactamase inhibitor combination for carbapenem-resistant enterobacterales infections. Infect Dis Ther. 2020;9(4):757–67.
- Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, Brizendine KD, Mathers AJ. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother. 2018;63(1):e01551–18.
- Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis. 2020;7:2049936120912049
- Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing klebsiella pneumoniae. Microb Drug Resist. 2019;25(9):1357–64.
- Romanelli F, De Robertis A, Carone G, Dalfino L, Stufano M, Del Prete R, Mosca A. In vitro activity of ceftazidime/avibactam alone and in combination with fosfomycin and carbapenems against kpc-producing klebsiella pneumoniae. New Microbiol. 2020;43(3):136–8.
- Iannaccone M, Boattini M, Bianco G, Cavallo R, Costa C. Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2020;56(2):106066
- Gaibani P, Ambretti S, Viale P, Re MC. In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2019;74(5):1457–9.